BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18045060)

  • 1. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
    Johnson FM; Gallick GE
    Anticancer Agents Med Chem; 2007 Nov; 7(6):651-9. PubMed ID: 18045060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
    Benati D; Baldari CT
    Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic SRC-kinase domain inhibitors and their structural requirements.
    Schenone S; Manetti F; Botta M
    Anticancer Agents Med Chem; 2007 Nov; 7(6):660-80. PubMed ID: 18045061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src family kinases in tumor progression and metastasis.
    Summy JM; Gallick GE
    Cancer Metastasis Rev; 2003 Dec; 22(4):337-58. PubMed ID: 12884910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src kinase inhibitors: promising cancer therapeutics?
    Creedon H; Brunton VG
    Crit Rev Oncog; 2012; 17(2):145-59. PubMed ID: 22471705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Src continues aging: current and future clinical directions.
    Kopetz S; Shah AN; Gallick GE
    Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Src in solid tumors.
    Wheeler DL; Iida M; Dunn EF
    Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
    Lieu C; Kopetz S
    Clin Colorectal Cancer; 2010 Apr; 9(2):89-94. PubMed ID: 20378502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress of SRC family kinase inhibitors as anticancer agents.
    Cao X; You QD; Li ZY; Wang XJ; Lu XY; Liu XR; Xu D; Liu B
    Mini Rev Med Chem; 2008 Sep; 8(10):1053-63. PubMed ID: 18782057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
    Zhang S; Yu D
    Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonreceptor tyrosine kinases in prostate cancer.
    Chang YM; Kung HJ; Evans CP
    Neoplasia; 2007 Feb; 9(2):90-100. PubMed ID: 17357254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src inhibitors in breast cancer therapy.
    Hiscox S; Nicholson RI
    Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src signaling in cancer invasion.
    Guarino M
    J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basis and importance of Src as a target in cancer.
    Levin VA
    Cancer Treat Res; 2004; 119():89-119. PubMed ID: 15164875
    [No Abstract]   [Full Text] [Related]  

  • 18. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRC: a century of science brought to the clinic.
    Aleshin A; Finn RS
    Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src-family tyrosine kinases as therapeutic targets in advanced cancer.
    Gelman IH
    Front Biosci (Elite Ed); 2011 Jun; 3(3):801-7. PubMed ID: 21622091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.